A Study of Effect of Megakaryocytes and Platelets in Breast Cancer

Inclusion Criteria: Cohort 1-Biopsy negative * Females age 18 and above Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other) * Females age 18 and above * Any subtype of breast cancer Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other) * Females age 18 and above * Any subtype of breast cancer * Have no distant metastases Cohort 4-Stage 4 Metastatic Disease * Females age 18 and above * Any subtype of breast cancer Exclusion Criteria: * Previous diagnosis with a known platelet disorder such as: Bernard Soulier disease, Jacobsen syndrome, Lowe syndrome, Thrombocytopenia, Thrombotic thrombocytopenic pupura, Von Willebrand disease, or the equivalent. Any condition in which antiplatelet or anticoagulant therapy with one of the following medications is being prescribed: Clopidogrel (Plavix), Warfarin (Coumadin or Jantoven), Prasugrel (Effient), or Ticagrelor (Brilinta). Cohort 1-Biopsy negative * Males * Females less than age 18 Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other) * Males * Females less than age 18 * Currently undergoing neoadjuvant therapy Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other) * Males * Females less than age 18 * Presence of distant metastases * Currently undergoing neoadjuvant therapy Cohort 4-Stage 4 Metastatic Disease * Males * Females less than age 18 * Currently undergoing neoadjuvant therapy * Less than 30 days from last adjuvant treatment for Stage I-III Breast Cancer (may be on Trastuzumab, Pertuzumab, or endocrine therapy only for maintenance therapy from their prior breast cancer diagnosis)